**************Clascoterone and PP405 advance as topical hair loss innovations** [developing]** [developing]** [developing]** [developing]** [developing]** [developing]
Key Questions
What are the key findings from Phase 3 trials of clascoterone for hair loss?
Phase 3 SCALP data shows clascoterone 5% topical solution blocks DHT in hair follicles with minimal absorption, offering an alternative to oral treatments. Twelve-month data confirms positive safety for chronic use and statistically significant continued hair growth.
How does PP405 work for hair loss treatment?
PP405 is a Phase 2a topical that activates stem cells in hair follicles without systemic side effects. It represents an innovative approach in the pipeline for topical hair loss therapies.
What is iRestore and its status for hair growth?
iRestore offers FDA-cleared low-level light therapy (LLLT) helmets for hair growth, currently available with discounts up to $900. It complements other scalp trends like Keravive from AAD discussions.
Phase 3 SCALP 12-month data confirms safety like vehicle, statistically significant continued hair growth (2.39x TAHC gain vs decline in switch-off), viable chronic use for male AGA (NDA 2027); PP405 Phase 2a stem topical no sys sides; iRestore LLLT FDA-cleared; AAD scalp (Keravive/Dove/Neutrogena/PRP/exosomes); GLP-1 hair loss guide. Reg timelines, efficacy, sequencing watch.